UTRECHT, The Netherlands--(BUSINESS WIRE)--Sapreme, a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutics, today announced that it has closed a EUR 15 ...
Entrada Therapeutics is developing endosomal escape vehicles (EEV) to deliver oligonucleotides for neuromuscular diseases. Despite having no clinical data, the company has a market cap of nearly ...
April 4, 2022 (Kawasaki, Japan) - Innovation Center of NanoMedicine (Director General: Prof. Kazunori Kataoka) has announced that Prof. Satoshi Uchida et al. presented their research results about ...
Protein-based drugs must be transported into cells in a way that prevents their immediate degradation. A new approach is intended to ensure that they remain intact only in certain cells, such as ...
UTRECHT, the Netherlands--(BUSINESS WIRE)--Sapreme, a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutics, today announced positive preclinical data on ...
New non-human primate data demonstrate a durability of response through 12 weeks for lead clinical candidate, ENTR-601-44, for the potential treatment of Duchenne muscular dystrophy Second clinical ...
The latest short science news items from C&EN. A complicated sequence of events follows once an RNA drug is injected into the body. After the lipid-packaged RNA arrives at a cell, it pushes through ...
Macromolecules such as peptides, proteins and siRNAs show great promise as therapeutic agents in precision medicine, but their large size complicates delivery into the cytoplasm or nucleus. Adding ...
A study recently published in the Journal of Cell Biology has demonstrated the endosomal transport process of nanoparticle-based formulations that leads to the effective delivery of messenger ...
RNA-based drugs have been slow to realize their therapeutic promise because they often find themselves trapped in endosomes and delivered to degradative lysosomes. Yet if RNA-based drugs could be ...
(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) and Entrada Therapeutics Inc. (TRDA) have established collaboration to discover and develop endosomal escape vehicle therapeutics for Myotonic Dystrophy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback